

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

Attachment 4
July 14, 2026

【Therapeutic category】 339 Other agents relating to blood and body fluids

【Non-proprietary name】 Aspirin/vonoprazan fumarate

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
8. IMPORTANT PRECAUTIONS (N/A)	8. IMPORTANT PRECAUTIONS <u>Prolonged use of vonoprazan may cause hypomagnesaemia. Blood magnesium levels should be periodically measured when long-term treatment with this drug is deemed necessary.</u>
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Hypomagnesaemia</u> <u>Prolonged use of vonoprazan may cause hypomagnesaemia accompanied by symptoms such as prolonged QT, convulsion, and numbness. Electrolyte abnormalities such as hypocalcaemia and hypokalaemia caused by hypomagnesaemia may also occur. If any symptoms suggestive of these electrolyte abnormalities occur, blood magnesium levels should be measured. If any abnormality is observed, appropriate measures should be taken such as magnesium replacement.</u>

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.